Adeyinka O Laiyemo1,2,3, Chyke Doubeni4, Paul F Pinsky5, V Paul Doria-Rose6, Robert Bresalier7, Thomas Hickey8, Thomas Riley8, Tim R Church9, Joel Weissfeld10, Robert E Schoen10, Pamela M Marcus6, Philip C Prorok11. 1. Department of Medicine, Howard University College of Medicine, Washington, DC, USA. adeyinka.laiyemo@howard.edu. 2. Biometry Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. adeyinka.laiyemo@howard.edu. 3. Division of Gastroenterology, Department of Medicine, Howard University College of Medicine, 2041 Georgia Avenue, NW, Washington, DC, 20060, USA. adeyinka.laiyemo@howard.edu. 4. Department of Family Medicine and Community Health at the Perelman School of Medicine, Leonard Davis Institute for Health Economics, and the Center for Public Health Initiatives, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. 5. Early Detection Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 6. Health Services and Economics Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 7. M.D. Anderson Cancer Center, Houston, TX, USA. 8. Information Management Services Inc., Rockville, MD, USA. 9. Department of Environmental Health Sciences, School of Public Health, University of Minnesota, Minneapolis, MN, USA. 10. Department of Medicine and Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA. 11. Biometry Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Abstract
BACKGROUND: It is unclear whether the higher rate of colorectal cancer (CRC) among non-Hispanic blacks (blacks) is due to lower rates of CRC screening or greater biologic risk. OBJECTIVE: We aimed to evaluate whether blacks are more likely than non-Hispanic whites (whites) to develop distal colon neoplasia (adenoma and/or cancer) after negative flexible sigmoidoscopy (FSG). DESIGN: We analyzed data of participants with negative FSGs at baseline in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial who underwent repeat FSGs 3 or 5 years later. Subjects with polyps or masses were referred to their physicians for diagnostic colonoscopy. We collected and reviewed the records of diagnostic evaluations. PARTICIPANTS: Our analytic cohort consisted of 21,550 whites and 975 blacks. MAIN MEASURES: We did a comparison by race (whites vs. blacks) in the findings of polyps or masses at repeat FSG, the follow-up of abnormal test results and the detection of colorectal neoplasia at diagnostic colonoscopy. KEY RESULTS: At the follow-up FSG examination, 304 blacks (31.2 %) and 4183 whites (19.4 %) had abnormal FSG, [adjusted relative risk (RR) = 1.00; 95 % confidence interval (CI), 0.90-1.10]. However, blacks were less likely to undergo diagnostic colonoscopy (76.6 % vs. 83.1 %; RR = 0.90; 95 % CI, 0.84-0.96). Among all included patients, blacks had similar risk of any distal adenoma (RR = 0.86; 95 % CI, 0.65-1.14) and distal advanced adenoma (RR = 1.01; 95 % CI, 0.60-1.68). Similar results were obtained when we restricted our analysis to compliant subjects who underwent diagnostic colonoscopy (RR = 1.01; 95 % CI, 0.80-1.29) for any distal adenoma and (RR = 1.18; 95 % CI, 0.73-1.92) for distal advanced adenoma. CONCLUSIONS: We did not find any differences between blacks and whites in the risk of distal colorectal adenoma 3-5 years after negative FSG. However, follow-up evaluations were lower among blacks.
RCT Entities:
BACKGROUND: It is unclear whether the higher rate of colorectal cancer (CRC) among non-Hispanic blacks (blacks) is due to lower rates of CRC screening or greater biologic risk. OBJECTIVE: We aimed to evaluate whether blacks are more likely than non-Hispanic whites (whites) to develop distal colon neoplasia (adenoma and/or cancer) after negative flexible sigmoidoscopy (FSG). DESIGN: We analyzed data of participants with negative FSGs at baseline in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial who underwent repeat FSGs 3 or 5 years later. Subjects with polyps or masses were referred to their physicians for diagnostic colonoscopy. We collected and reviewed the records of diagnostic evaluations. PARTICIPANTS: Our analytic cohort consisted of 21,550 whites and 975 blacks. MAIN MEASURES: We did a comparison by race (whites vs. blacks) in the findings of polyps or masses at repeat FSG, the follow-up of abnormal test results and the detection of colorectal neoplasia at diagnostic colonoscopy. KEY RESULTS: At the follow-up FSG examination, 304 blacks (31.2 %) and 4183 whites (19.4 %) had abnormal FSG, [adjusted relative risk (RR) = 1.00; 95 % confidence interval (CI), 0.90-1.10]. However, blacks were less likely to undergo diagnostic colonoscopy (76.6 % vs. 83.1 %; RR = 0.90; 95 % CI, 0.84-0.96). Among all included patients, blacks had similar risk of any distal adenoma (RR = 0.86; 95 % CI, 0.65-1.14) and distal advanced adenoma (RR = 1.01; 95 % CI, 0.60-1.68). Similar results were obtained when we restricted our analysis to compliant subjects who underwent diagnostic colonoscopy (RR = 1.01; 95 % CI, 0.80-1.29) for any distal adenoma and (RR = 1.18; 95 % CI, 0.73-1.92) for distal advanced adenoma. CONCLUSIONS: We did not find any differences between blacks and whites in the risk of distal colorectal adenoma 3-5 years after negative FSG. However, follow-up evaluations were lower among blacks.
Entities:
Keywords:
PLCO; adenomatous polyps; colorectal cancer disparities; flexible sigmoidoscopy; screening
Authors: Lina Jandorf; Anne Fatone; Priti V Borker; Mark Levin; Warria A Esmond; Barbara Brenner; Gary Butts; William H Redd Journal: Cancer Date: 2006-10-15 Impact factor: 6.860
Authors: D K Rex; O W Cummings; D J Helper; T V Nowak; J M McGill; G Z Chiao; P Y Kwo; K T Gottlieb; S O Ikenberry; F G Gress; G A Lehman; L J Born Journal: Gastroenterology Date: 1996-11 Impact factor: 22.682
Authors: Chyke A Doubeni; Terry S Field; Diana S M Buist; Eli J Korner; Carol Bigelow; Lois Lamerato; Lisa Herrinton; Virginia P Quinn; Gene Hart; Mark C Hornbrook; Jerry H Gurwitz; Edward H Wagner Journal: Cancer Date: 2007-02-01 Impact factor: 6.860
Authors: P C Prorok; G L Andriole; R S Bresalier; S S Buys; D Chia; E D Crawford; R Fogel; E P Gelmann; F Gilbert; M A Hasson; R B Hayes; C C Johnson; J S Mandel; A Oberman; B O'Brien; M M Oken; S Rafla; D Reding; W Rutt; J L Weissfeld; L Yokochi; J K Gohagan Journal: Control Clin Trials Date: 2000-12
Authors: Temeika L Fairley; Cheryll J Cardinez; Jim Martin; Linda Alley; Carol Friedman; Brenda Edwards; Patricia Jamison Journal: Cancer Date: 2006-09-01 Impact factor: 6.860
Authors: Paul F Pinsky; Robert E Schoen; Joel L Weissfeld; Barnett Kramer; Richard B Hayes; Lance Yokochi Journal: Clin Gastroenterol Hepatol Date: 2005-08 Impact factor: 11.382
Authors: David A Lieberman; Jennifer L Holub; Matthew D Moravec; Glenn M Eisen; Dawn Peters; Cynthia D Morris Journal: JAMA Date: 2008-09-24 Impact factor: 56.272
Authors: Carolyn M Rutter; Amy B Knudsen; Jennifer S Lin; Kathryn E Bouskill Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-11-03 Impact factor: 4.090